Hematopoietic progenitor cell transplantation in breast cancer: Current status and future directions

Cancer Investigation

Volumn 16, Issue 2, 1998, Pages 102-126

  Lazarus, Hillard M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Autologous and allogeneic transplantation; Breast cancer; Cytokines; Hematopoietic progenitor cells; High dose chemotherapy; Human bone marrow; Immunotherapy; Stem cells; Stroma; Tumor detection

Indexed keywords

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031892906     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039764     Document Type: Review

References (317)

1. Wingo P, Tong T, Bolden S: Cancer statistics. CA - A Cancer Journal for Clinicians 45:8-30, 1995.
2. Hortobagyi GN: Overview of new treatments for breast cancer. Breast Cancer Res Treat 21:3-13, 1992.
3. Mick R, Begg CB, Antman KH, et al: Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies? Breast Cancer Res Treat 13:33-38, 1989.
4. Legha SS, Buzdar AU, Smith TL, et al: Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 91:847-852, 1979.
5. Greenberg PAC, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996.
6. Gregory WM, Smith P, Richards MA, et al: Chemotherapy of advanced breast cancer: Outcome and prognostic factors. Br J Cancer 68:988-995, 1993.
7. Fisher B, Bauer M, Margolese R, et al: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312:665-673, 1985.
8. Fisher B, Redmond C, Poisson R, et al: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822-828, 1989.
9. Veronesi U, Saccozzi R, Del Vecchio M, et al: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radio-therapy in patients with small cancer of the breast. N Engl J Med 305:6-11, 1981.
10. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy: Analysis of 716 consecutive patients. Cancer 41:1170-1178, 1978.
11. Fisher E, Sass R, Fisher B: Pathologic findings from the national surgical adjuvant breast project for breast cancers (protocol no. 4). Cancer 53:712-723, 1984.
12. Nemoto T, Vana J, Bedwani RN, et al: Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45:2917-2924, 1980.
13. Clark GM, Sledge GW Jr, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61, 1987.
14. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987.
15. Falkson G, Gelman RS, Tormey DC, et al: The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56:219-224, 1985.
16. Rainey JM, Jones SE, Salmon SE: Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC). Cancer 43:66-71, 1979.
17. Theriault RL, Hortobagyi GN, Kau SW, et al: Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer 62:2105-2110, 1988.
18. Henderson IC: Chemotherapy for advanced disease. In: Breast Diseases, edited by JR Harris, S Hellman, IC Henderson, DW Kenne, Philadelphia, JB Lippincott, 1987, pp 428-479.
19. Hortobagyi GN, Buzdar AU, Bodey GP, et al: High-dose induction chemotherapy of metastatic breast cancer in protected environment: A prospective randomized study. J Clin Oncol 5:178-184, 1987.
20. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992.
21. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995.
22. Breast cancer: Have we lost our way? (editorial). Lancet 341:343-344, 1993.
23. Triozzi PL: Autologous bone marrow and peripheral blood progenitor transplant for breast cancer. Lancet 344:418-419, 1994.
24. Schabel FM: Animal models as predictive systems. In: Cancer Chemotherapy: Fundamental Concepts and Recent Advances, Chicago, Year Book Medical, 1975, pp 323-355.
25. Teicher B, Holden SA, Cucchi CA, et al: Combination of N,N′,N″-triethylenethiophosphamide and cyclophosphamide in vitro and m vivo. Cancer Res 48:94-100, 1988.
26. Frei E III, Cucchi C, Rosowsky A, et al: Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158-2162, 1985.
27. Hyriniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984.
28. Frei E III, Antman K, Teicher B, et al: Review article: Bone marrow autotransplantation for solid tumors - prospects. J Clin Oncol 7:515-526, 1989.
29. Frei E III, Teicher BA, Holden SA, et al: Effect of alkylating agent dose: Studies and possible clinical correlation. Cancer Res 48:6417-6432, 1988.
30. DeVita VT Jr: Dose-response is alive and well. J Clin Oncol 4:1157-1159, 1986.
31. Hryniuk WM: The importance of dose-intensity in the outcome of chemotherapy. In: Advances in Oncology, edited by VT DeVita Jr, S Hellman, SA Rosenberg, Philadelphia, Lippincott, 1988, pp 121-141.
32. Cheson BD, Lacerna L, Leyland-Jones B, et al: Review: Autologous bone marrow transplantation: Current status and future directions. Ann Intern Med 110:51-65, 1989.
33. Tannock IF, Boyd NF, De Boer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988.
34. Teicher BA, Cucci CA, Lee JB, et al: Alkylating agents: In vitro studies of cross resistance patterns in human cell lines. Cancer Res 46:4379-4383, 1986.
35. Hyriniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986.
36. Bonnadonna G, Valagusa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981.
37. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994.
38. Stewart THM, Retsky MW, Tsai SCJ, et al: Dose response in the treatment of breast cancer. Lancet 343:402-404, 1994.
39. Skipper HE, Schabel FM, Jary R, et al: Experimental evaluation of potential antitumor agents. Cancer Chemother Rep 35:1-111, 1964.
40. O'Dwyer PJ, LaCreta FP, Schilder R, et al: Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10:1352-1358, 1992.
41. O'Dwyer PJ, LaCreta F, Engstrom PF, et al: Phase I pharmaco-kinetic reevaluation of thiotepa. Cancer Res 51:3171-3176, 1991.
42. Lazarus HM, Reed MD, Spitzer TR, et al: High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:689-695, 1987.
43. Antman K, Bearman SI, Davidson N, et al: Dose intensive therapy in breast cancer: current status. In: New Strategies in Bone Marrow Transplantation, edited by RE Champlin, RP Gale, New York, Wiley-Liss, 1991, pp 423-436.
44. Peters WP, Eder JP, Henner WP, et al: High dose combination alkylating agents with autologous bone marrow support: A phase I trial. J Clin Oncol 4:646-654, 1986.
45. Antman K, Eder JP, Elias A, et al: High dose combination alkylating agent preparative regimens with autologous bone marrow support: The Dana Farber Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119-125, 1987.
46. Slease RB, Benear JB, Selby GB, et al: High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 6:1314-1320, 1988.
47. Eder JP, Antman K, Elias A: Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 80:1221-1226, 1988.
48. Eder JP, Elias A, Shea TC, et al: A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8:1239-1245, 1990.
49. Moormeier JA, Williams SF, Kaminer LS, et al: High dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst 82:29-34, 1990.
50. Schabel FM, Trader NW, Laster WR Jr, et al: Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 23:200-215, 1978.
51. Schabel FM: Synergism and antagonism among antitumor agents. In: The Pharmacological Basis of Cancer Chemotherapy, Baltimore, Williams & Wilkins, 1975, pp 595-623.
52. Thomas ED, Buckner CD, Banaji M, et al: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49:511-533, 1977.
53. Phillips GL, Herzig RH, Lazarus HM, et al: Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and cryopreserved autologous marrow transplantaion. N Engl J Med 310:1567-1571, 1984.
54. Cole HM: Questions and answers. Diagnostic & Therapeutic Technology Assessment (DATTA). J Am Med Assoc 263:881-887, 1990.
55. Bortin MM, Horowitz MM, Gale RP, et al: Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. J Am Med Assoc 268:607-612, 1992.
56. Eddy DM: Review article: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10:657-670, 1992.
57. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988.
58. Antman K, Ayash L, Elias A, et al: A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992.
59. Holland HK, Dix SP, Geller RB, et al: Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 14:1156-1164, 1996.
60. Klumpp TR, Mangan KF, Glenn LD, et al: Phase n pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 11:337-339, 1993.
61. Demirer T, Buckner CD, Appelbaum FR, et al: High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 17:769-774, 1996.
62. Kalaycioglu ME, Lichtin AE, Andresen SW, et al: High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 18:491-494, 1995.
63. Williams SF, Gilewski T, Mick R, et al: High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10:1743-1747, 1992.
64. Kennedy MJ, Beveridge RA, Rowley SD, et al: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920-926, 1991.
65. Myers SE, Mick R, Williams SF: High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplant. Bone Marrow Transplant 13:449-454, 1994.
66. Gisselbrecht C, Extra JM, Lotz JP, et al: Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 18:857-863, 1996.
67. Crown J, Kritz A, Vahdat L, et al: Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 11:1144-1149, 1993.
68. deMagalhaes-Silverman M, Rybka WB, Lembersky B, et al: High-dose cyclophoshamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer. Am J Clin Oncol 19:169-173, 1996.
69. Erban J, Miller K, Berkman E, et al: High dose chemotherapy with stem cell rescue following hormonal recruitment in women with stage IIIA-IV breast cancer in remission (abstract 146). Proc Am Soc Clin Oncol 15:120, 1996.
70. Fields KK, Elfenbein GJ, Lazarus HM, et al: Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile. J Clin Oncol 13:323-332, 1995.
71. Lazarus HM, Gray R, Ciobanu N, et al: A phase I trial of high-dose melphalan, high-dose etoposide, and autologous bone marrow re-infusion in solid tumors: An Eastern Cooperative Oncology Group (ECOG) study. Bone Marrow Transplant 14:443-448, 1994.
72. Weaver CH, Bensinger WI, Appelbaum FR, et al: Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 14:813-819, 1994.
73. Stemmer SM, Cagnoni PJ, Shpall EJ, et al: High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial. J Clin Oncol 14:1463-1472, 1996.
74. Broun ER, Sledge GW, Walsh WK, et al: Dose escalation of Taxol with high dose carboplatin/cyclophosphamide and PBSC support in stage IV breast cancer (abstract 1003). Proc Am Soc Clin Oncol 15:344, 1996.
75. Somlo G, Doroshow JH, Forman SJ, et al: High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 73:1678-1685, 1994.
76. Somlo G, Doroshow JH, Forman SJ, et al: High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell rein-fusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 73:125-134, 1994.
77. Vaughan WP, Reed EC, Edwards B, Kessinger A: High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stern cell rescue: An effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 13:619-624, 1994.
78. Saez RA, Selby GB, Slease RB, et al: Autologous bone marrow transplantation for metastatic breast cancer. J Okla State Med Assoc 87:405-110, 1994.
79. Gianni AM, Siena S, Bregni M, et al: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15:2312-2321, 1997.
80. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993.
81. Broun ER, Petruska PJ, Dunphy FR, et al: Taxol plus carboplatin/cyclophosphamide and peripheral blood stem cell (PBSC) support in stage II/III breast cancer (abstract 1002). Proc Am Soc Clin Oncol 15:344, 1996.
82. Spitzer TR, Cirenza E, McAfee S, et al: Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 15:537-542, 1995.
83. Razis ED, Samonis G, Cook P, et al: TMJ: A well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. J Med 25:241-250, 1994.
84. Tomás JF, Pérez-Carrión R, Escudero A, et al: Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 19:331-336, 1997.
85. Peters WP, Fay JW, Holland HK, et al: Autologous bone marrow transplantation as adjuvant therapy in primary breast cancer: The American experience. Bone Marrow Transplant 15(Suppl 1):S254-S259, 1995.
86. Livingston RB, Schulman S, Griffin BR, et al: Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. Cancer 59:1249-1254, 1987.
87. Gisselbrecht C, Lepage E, Espie M, et al: Cyclophosphamide, total body irradiation with autologous bone marrow support for metastatic breast cancer (abstract 255). Proc Am Soc Clin Oncol 6:65, 1987.
88. Gisselbrecht C, LePage E, Extra J, et al: Inflammatory and metastatic breast cancer: cyclophosphamide and total body irradiation (TBI) with autologous bone marrow transplantation (ABMT). In: Autologous Bone Marrow Transplantation: Proceedings of the Fourth International Symposium, edited by K Dicke, G Spitzer, S Jagannath, Houston, University of Texas, MD Anderson Cancer Center Press, 1989, pp 363-367.
89. Gandola L, Siena S, Bregni M, et al: Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation. Int J Radiat Oncol Biol Phys 19:743-749, 1990.
90. Huber C, Niederwieser D, Schonitzer D, et al: Liver transplantation followed by high-dose cyclophosphamide, total-body irradiation, and autologous bone marrow transplantation for treatment of metastatic breast cancer. A case report. Transplantation 37:311-312, 1984.
91. Stewart PS: Autologous bone marrow transplantation in metastatic breast cancer. Breast Cancer Res Treat 2:85-92, 1982.
92. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382-1388, 1987.
93. Avalos B, Tutschka PJ, Kapoor N, et al: Busulfan and cyclophosphamide as a preparative regimen for marrow transplantation for lymphoma. Exp Hematol 18:421-425, 1990.
94. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 177:655-667, 1979.
95. Horwitz SB: Mechanism of action of Taxol. Trends Pharmacol Sci 13:134-136, 1992.
96. Milas L, Hunter NR, Kurdoglu B, et al: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 35:297-303, 1995.
97. McCloskey DE, Davidson NE: Paclitaxel-induced programmed cell death in human breast cancer cells (abstract 2482). Proc Am Assoc Cancer Res 36:416, 1995.
98. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993.
99. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991.
100. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1009, 1995.
101. Shea T, Graham M, Bernard S, et al: Multiple cycles of high dose paclitaxel plus escalating doses of carboplatin with G-CSF (filgrastim) and peripheral blood stem cell (PBSC) support (abstract 1555). Proc Am Soc Clin Oncol 14:478, 1995.
102. Fields K, Perkins J, Elfenbein G, et al: A phase I dose escalation trial of high dose Taxol®, Novantrone®, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR): Toxicity (abstract 953). Proc Am Soc Clin Oncol 14:322, 1995.
103. Falkson G, Gelman RS, Pretorius FJ: Age as a prognostic factor in recurrent breast cancer. J Clin Oncol 4:663-671, 1986.
104. Fey MF, Brunner KW, Sonntag RW: Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4:237-247, 1981.
105. Tormey DC, Carbone P, Band P: Breast cancer survival in single and combination chemotherapy trials since 1968 (abstract). Proc Am Assoc Cancer Res 18:64, 1977.
106. Henderson IC: Chemotherapy for metastatic disease. In: Breast Diseases, edited by JR Harris, S Hellman, IC Henderson, DW Kinne, Philadelphia, JB Lippincott, 1991, pp 604-665.
107. Gradishar WJ, Tallman MS, Abrams JS: High-dose chemotherapy for breast cancer. Ann Intern Med 125:599-604, 1996.
108. Jones VE, Raghaven D: Quantum leaps in treatment of high-risk breast cancer? Prove it! Eur J Cancer 29A: 1488-1493, 1993.
109. Canellos GP: Autologous bone marrow or stem cell transplantation following high-dose chemotherapy for breast cancer: What is the true story? Breast Diseases: A Year Book Quarterly 6:19-20, 1995.
110. Kennedy MJ: High-dose chemotherapy of breast cancer: Is the question answered? J Clin Oncol 13:2477-2479, 1995.
111. Davidson NE: Out of the courtroom and into the clinic. J Clin Oncol 10:517-519, 1992.
112. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995.
113. Antman KH, Rowlings PA, Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997.
114. Ayash L, Wheeler C, Fairclough D, et al: Prognostic factors for prolonged disease-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13:2043-2049, 1995.
115. Dunphy FR, Spitzer G, Rossiter Fornoff JE, et al: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73:2157-2167, 1994.
116. Bearman SI, Jones RB, Shpall EJ, et al: High-dose chemotherapy with autologous progenitor cell support for stage IV NED breast cancer (abstract 194). Proc Am Soc Clin Oncol 13:98, 1994.
117. Norton L: A Gompertian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988.
118. Norton L, Simon R: Tumor size, sensitivity to therapy and the design of treatment schedules. Cancer Treat Rep 61:1307-1317, 1977.
119. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990.
120. Pittman KB, To LB, Bayly JL, et al: Non-haematologic toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transplant 10:535-540, 1992.
121. Ayash LJ, Elias A, Wheeler C, et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37-44, 1994.
122. Bitran JD, Samuels B, Klein L, et al: Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17:157-162, 1996.
123. Broun ER, Sridhara R, Sledge GW, et al: Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13:2050-2055, 1995.
124. Ho AD, Mason J, Mulroney C, et al: Sequential high-dose chemotherapy with alternating regimens and stem cell support for patients with metastatic breast cancer (abstract 188). Proc Am Soc Clin Oncol 13:96, 1994.
125. Somlo G, Doroshow JH, Forman S, et al: Double cycle (C) high-dose melphalan (MEL) and cisplatin (CDDP) followed by peripheral stem cell (PSC) rescue (abstract 219). Proc Am Soc Clin Oncol 13:104, 1994.
126. Crown J, Raptis G, Vahdat L, et al: Rapid administration of sequential high dose (HD) cyclophosphamide (CPA), melphalan (M), thiotepa (TT) supported by filgrastim (G) + peripheral blood progenitors (PBP) in patients (pts) with metastatic breast cancer (MBC): A novel and very active treatment strategy (abstract 242). Proc Am Soc Clin Oncol 13:110, 1994.
127. Wallerstein R Jr, Spitzer G, Dunphy F, et al: A phase II study of mitoxantrone, etoposide, and thiotepa with autologous bone marrow support for patients with relapsed breast cancer. J Clin Oncol 8:1782-1788, 1990.
128. Crown J, Vahdat L, Raptis G, et al: Rapidly cycled courses of high-dose (HD) chemotherapy (C) supported by filgrastim (G) and peripheral blood progenitors (PBP) in patients (pts) with metastatic breast cancer (MBC) (abstract 243). Proc Am Soc Clin Oncol 13:110, 1994.
129. Ghalie R, Williams SF, Valentino LA, et al: Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1:40-46, 1995.
130. Kennedy MJ, Armstrong DK, Huelskamp AM, et al: Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 13:1136-1143, 1995.
131. Kennedy MJ, Armstrong DK, Bond S, et al: Phase II study of novobiocin (N) in combination with high-dose alkylating agent chemotherapy (HDC) for patients (PTS) with advanced breast cancer (BC) (abstract 966). Proc Am Soc Clin Oncol 15:335, 1996.
132. Dimitrov N, Anderson S, Fisher B, et al: Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22 (abstract 58). Proc Am Soc Clin Oncol 13:64, 1994.
133. Bearman SI, Overmoyer BA, Bolwell BJ, et al: High-dose chemotherapy with autologous peripheral blood progenitor cells (PBPC) for stage II/III breast cancer in patients with 4-9 involved axillary lymph nodes (abstract 232). Proc Am Soc Clin Oncol 14:133, 1995
134. Peters WP, Jones RB, Vredenburgh J, et al: A large, prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (abstract 149). Proc Am Soc Clin Oncol 15:121, 1996.
135. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl I Med 318:869-876, 1988.
136. Aurer I, Ribas A, Gale RP: What is the role of recombinant colony-stimulating factors in bone marrow transplantation? Bone Marrow Transplant 6:79-87, 1990.
137. Mertelsmann R, Herrmann F, Hecht T, et al: Hematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant 6:73-7, 1990.
138. Körbling M, Dorken B, Ho AD, et al: Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 67:529-532, 1986.
139. Kessinger A, Armitage JO, Landmark JD: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723-727, 1988.
140. Lowry PA, Tabbara IA: Mini review: Peripheral hematopoietic stem cell transplantation: Current concepts. Exp Hematol 20:937-942, 1992.
141. Elias AD, Ayash L, Anderson KC, et al: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79:3036-3044, 1992.
142. Myers SE, Williams SF, Geller RB: Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplant after high dose chemotherapy: Clinical results in patients with contaminated or hypocellular bone marrow. J Hematother 1:27-33, 1992.
143. Ho AD, Glück S, Germond C, et al: Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 7:1738-1746, 1993.
144. Williams SF: Application of peripheral blood progenitors to dose intensive therapy of breast cancer. Breast Cancer Res Treat 26 (Suppl 1):25-29, 1993.
145. To LB, Shepperd KM, Haylock DN, et al: Single high dose of Cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18:442-447, 1990.
146. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet ii:580-585, 1989.
147. Bishop MR, Anderson JR, Jackson JD, et al: High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 83:610-616, 1994.
148. Iacone A, Pierelli L, Quaglietta AM, et al: Survival after PBSC transplantation and comparison of engraftment speed with autologous and allogeneic marrow transplantation: Results of multi-center study. Int J Artif Organs 16 (S-5):45-50, 1993.
149. To LB, Roberts MM, Haylock DN, et al: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants, Bone Marrow Transplant 9:277-284, 1992.
150. Peters WP, Rosner G, Ross M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709-1719, 1993.
151. Chao NJ, Schriber JR, Grimes K, et al: Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031-2035, 1993.
152. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992.
153. Janssen WE, Smilee RC, Elfenbein GJ: A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy (letter). J Hematother 4:139-140, 1995.
154. + cells. In: Advances in Bone Marrow Purging and Processing: Fourth International Symposium, New York, Wiley-Liss, 1994, pp 363-369.
155. Dicke KA, Hood DL, Arneson M, et al: Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol 25:34-38, 1997.
156. Lazarus HM, Horowitz MM, Nugent ML: Outcome of autotransplants in older adults (abstract 977). Proc Am Soc Clin Oncol 15:338, 1996.
157. Sharp JG: Micrometastases and transplantation. J Hematother 5:519-524, 1996.
158. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994.
159. Brugger W, Bross KJ, Giant M, et al: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636-640, 1994.
160. Shpall EJ, Jones RB: Release of tumor cells from bone marrow. Blood 83:623-625, 1994.
161. Brenner MK, Rill DR, Moan RC, et al: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85-86, 1993.
162. Brenner MK, Rill DR: Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother 3:33-36, 1994.
163. Grande M, Barbu V, Van Den Akker J, et al: Autologous bone marrow transplantation in ALL: relapse linked to infusion of tumor cells with the back-up marrow. Bone Marrow Transplant 14:477-480, 1994.
164. Sharp JG, Kessinger A, Mann S, et al: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the harvested marrow or infused hematopoietic harvest. J Clin Oncol 14:214-219, 1996.
165. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076, 1994.
166. Moss TJ, Sanders DG, Lasky LC, et al: Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 76:1879-1883, 1990.
167. + cells to remove circulating tumor cells. Blood 87:1625-1634, 1996.
168. Sharp JG, Crouse DA: Marrow contamination: detection and significance. In: High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, edited by JO Armitage, KH Amman, Baltimore, Williams & Wilkins, 1992, pp 226-248.
169. Sharp JG, Kessinger A, Vaughan WP, et al: Detection and clinical significance of minimal tumor contamination of peripheral blood stem cell harvests. Int J Cell Cloning 10(Suppl 1):92-94, 1992.
170. Vaughan WP, Mann SL, Garvey J, et al: Breast cancer detected in cell culture of histologically negative bone marrow predicts systemic relapse in patients with stage I, II, III and locally recurrent disease (abstract 27). Proc Am Soc Clin Oncol 9:9, 1990.
171. Ross AA, Cooper BW, Lazarus HM, et al: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605-2610, 1993.
172. Ybanez J, Lazarus H, Ross A, et al: Impact of occult tumor (OT) reinfusion on outcome after high-dose chemotherapy (HDC) in patients with advanced breast cancer (abstract 1532). Blood 86 (Suppl 1):386a, 1995.
173. Fields KK, Elfenbein GJ, Moscinski LC, et al: PCR detection of breast cancer cells in peripheral blood stem cell collections: Incidence and correlations (abstract 2484). Blood 86:624a, 1995.
174. Brockstein BE, Ross AA, Moss TJ, et al: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage patients undergoing high-dose chemotherapy. J Hematother 5:617-624, 1996.
175. Douer D, Chaiwun B, Glaspy J, et al: Analysis of peripheral blood progenitor cell (PBPC) harvests for occult breast cancer micrometastases using a sensitive immunohistochemical method (abstract 51). Proc Am Soc Clin Oncol 12:62, 1993.
176. Datta YH, Adams PT, Drobyski WR, et al: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475-482, 1994.
177. Passos-Coelho J, Ross AA, Davis JA, et al: Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex-vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 54:2366-2371, 1994.
178. Simpson SJ, Vachula M, Kennedy MJ, et al: Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 23:1062-1068, 1995.
179. Pecora AL, Lazarus H, Cooper B, et al: The incidence of breast cancer cell contamination in peripheral blood stem cell collections in relation to the mobilization regimen (abstract 1622). Blood 88(Suppl 1):408a, 1996.
180. Shpall EJ, Jones RB, Bearman SI, et al: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28-36, 1994.
181. Passos-Coelho J, Ross AA, Kahn DJ, et al: Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 14:2569-2575, 1996.
182. Passos-Coelho JL, Ross AA, Moss TJ, et al: Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 85:1138-1143, 1995.
183. Franklin WA, Shpall EJ, Williams S, et al: Immunohistochemical detection of breast cancer cells. Breast Cancer Res Treat 1997 (in press).
184. Anderson IC, Shpall EJ, Leslie DS, et al: Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 49:4659-4664, 1989.
185. Shpall EJ, Jones RB, Bast RC, et al: 4-Hydroperoxycyclo-phosphamid purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high dose chemotherapy and autologous bone marrow support: A phase I trial. J Clin Oncol 9:85-93, 1991.
186. Lazarus HM, Rowe JM, Goldstone AH: Does in vitro purging improve the outcome after autologous bone marrow transplantation? J Hematotherapy 2:457-466, 1994.
187. Morecki S, Pavlotzky F, Margel S, et al: Purging breast cancer cells in preparation for autologous bone marrow transplantation. Bone Marrow Transplant 1:357-363, 1987.
188. Shpall EJ, Bast RC, Joines WT, et al: Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7:145-151, 1991.
189. + cells that lack detectable T cell, B cell, and myeloid antigens produce colony-forming cells when cultured with marrow stromal cells. J Exp Med 172:355-361, 1990.
190. Baum CM, Weissman IL, Tsukamoto AS, et al: Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89:804-808, 1992.
191. Civin CI, Strauss LC, Brovall C, et al: A hematopoietic progenitor cell surface antigen defined by a monoclonal antigen raised against KG-1a cells. J Immunol 133:157-162, 1984.
192. Przepiorka D, Van Vlasselaer P, Huynh L, et al: Rapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by automated density gradient centrifugation. J Hematother 1997 (in press).
193. + marrow cells in patients with breast cancer or neuroblastoma. Blood 77:1717-1722, 1991.
194. Lane TA, Law P, Maruyama M, et al: Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85:275-282, 1995.
195. + hematopoietic stem cells from human peripheral blood by high-gradient magnetic cell sorting. Cytometry 14:384-392, 1993.
196. Mapara MY, Körner U, Hildebrandt M, et al: Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 89:337-344, 1997.
197. + cells using one step high gradient magnetic cell depletion (abstract 2485). Blood 86:624a, 1995.
198. + blood cells. Blood 87:4903-4909, 1996.
199. + hematopoietic progenitor cells. Cancer Invest 14:589-596, 1996.
200. +-selected peripheral blood progenitor cells mobilized by recombinant granulocyte-and granulocyte-macrophage colony-stimulating factors. Blood 86:2052-2054, 1995.
201. + hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy (abstract 321). Blood 82:83a, 1993.
202. Brugger W, Heimfeld S, Berenson R, et al: Reconstitution of hernatopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333:283-287, 1995.
203. Emerson SG: Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapies. Blood 87:3082-3088, 1996.
204. Szilvassy SJ, Hoffman R: Enriched hematopoietic stem cells: Basic biology and clinical utility. Biol Blood Marrow Transplant 1:3-17, 1995.
205. + cells in autologous stem cell transplantation for breast cancer. Blood 87:1687-1691, 1996.
206. Champlin R, Mehra R, Gajewski J, et al: Ex vivo expanded progenitor cell transplantation in patients with breast cancer (abstract 1166). Blood 86(Suppl 1):295a, 1995.
207. Alcorn MJ, Holyoake TL, Richmond L, et al: CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 14:1839-1847, 1996.
208. + progenitor cells (abstract 1165). Blood 86(Suppl 1):295a, 1995.
209. Stiff PJ, Oldenberg D, Hsi E, et al: Successful hematopoietic engraftment following high-dose chemotherapy using only ex vivo expanded bone marrow grown in Aastrom (stromal-based) bioreactors (abstract 309). Proc Am Soc Clin Oncol 16:88a, 1997.
210. Lazarus HM, Haynesworth SE, Gerson SL, et al: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells) [MFCs]: Implications for therapeutic use. Bone Marrow Transplant 16:557-564, 1995.
211. Lazarus HM, Haynesworth SE, Gerson SL, et al: Clinical trials using human bone marrow-derived mesenchymal (stromal) progenitor cells. In: Proceedings of the Keystone Meeting, edited by A Keating, Taos, New Mexico, February 1996.
212. Lazarus HM, Haynesworth SE, Gerson SL, et al: Human bone marrow-derived mesenchymal (stromal) progenitor cells [MFCs] cannot be recovered from peripheral blood progenitor cell collections. J Hematother 1997 (in press).
213. Eibl B, Schwaighofer H, Nachbaur D, et al: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508, 1996.
214. Körbling M, Przepiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659-1665, 1995.
215. Goldman J: Peripheral blood stem cells for allografting. Blood 85:1413-1415, 1995.
216. Russell NH, Hunter AE: Peripheral blood stem cells for allo-geneic transplantation. Bone Marrow Transplant 13:353-355, 1994.
217. Ottinger HD, Beelen DW, Scheulen B, et al: Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88:2775-2779, 1996.
218. + peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 88:4132-4138, 1996.
219. Koç ON, Allay JA, Lee K, et al: Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 23:46-65, 1996.
220. Allay J, Dumenco L, Koç O, et al: Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 85:3342-3351, 1995.
221. + peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85:566-574, 1995.
222. + cells. Blood 84:1408-1414, 1994.
223. Sorrentino B, Brandt S, Bodine D, et al: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99-103, 1992.
224. Allay JA, Davis BM, Gerson SL: In-vivo enrichment of MGMT transduced murine hematopoietic progenitors by BCNU treatment of MGMT transplanted mice. Exp Hematol, 1997 (in press).
225. R-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. Human Gene Therapy 4:331-354, 1993.
226. Hanania EG, Fu SQ, Zu Z, et al: Transduction of marrow cells before transplant with retroviral vectors which contain the multidrug resistance-1 (MDR-1) cDNA is associated with long term resistance to taxol and permits in vivo selection of genetically-modified cells after transplantation. J Invest Med 43(Suppl 2):278A, 1995.
227. Li M-X, Banerjee D, Zhao S, et al: Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83:3403-3408, 1994.
228. Maze R, Carney J, Kelley M, et al: Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci USA 93:206-210, 1996.
229. Allay J, Koç O, Davis B, et al: Retroviral-mediated gene transduction of the human alkyltransferase cDNA confers nitrosourea resistance to human hematopoietic progenitors. Clin Cancer Res 2:1353-1359, 1996.
230. 6-methylguanine-DNA methyltransferase in normal and malignant tissue of the breast. Cancer Invest 12:605-610, 1994.
231. Spiro TP, Willson JKV, Haaga J, et al: O6-benzylguanine and BCNU: establishing the biochemical modulatory dose in tumor tissue for O6-alkylguanine DNA alkyltransferase directed DNA repair (abstract 362). Proc Am Soc Clin Oncol 15:177, 1996.
232. Marks LB, Halperin EC, Prosnitz LR, et al: Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with ≥10 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 23:1021-1026, 1992.
233. Mundt AJ, Sibley GS, Williams S, et al: Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: Implications for the use of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 30:151-160, 1994.
234. Klingemann H-G, Phillips GL: Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 8:73-81, 1991.
235. Bilgrami S, Suva M, Cardoso A, Ascensao JL, et al: Immunotherapy with autologous bone-marrow transplantation: rationale and results. Exp Hematol 22:1039-1050, 1994.
236. Kennedy MJ, Vogelsang GB, Beveridge RA, et al: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow trnasplantation for breast cancer. J Clin Oncol 11:478-484, 1993.
237. Glazier AD, Tutschka PJ, Farmer ER, et al: Graft-versus-host disease in cyclosporine A treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 158:1-8, 1983.
238. Natali PG, Giacomini P, Bigotti A, et al: Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 43:660-668, 1983.
239. Bernard D, Maurizis J-C, Ruse F, et al: Presence of HLA-D/DR antigens on the membrane of breast tumor cells. Clin Exp Immunol 56:215-221, 1984.
240. Kennedy MJ, Vogelsang GB, Jones RJ, et al: Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249-257, 1994.
241. Kennedy MJ, Hess AD, Passos Coelho J-L, et al: Cyclosporine A (CsA) induces autologous graft vs. host disease (AGVHD) following high dose chemotherapy (HDC) supported with peripheral blood progenitor cell (PBPC) infusions alone (abstract 964). Proc Am Soc Clin Oncol 15:335, 1996.
242. Kennedy MJ, Hess AD, Passos Coelho J-L, et al: Autologous graft vs. host disease (AGVHD) as immune therapy after high dose chemotherapy (HDC) for metastatic breast cancer (MBC): medium-term follow up and comparison with historical controls (abstract 965). Proc Am Soc Clin Oncol 15:335, 1996.
243. Ellis TM, McKenzie RS, Simms PE, et al: Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 143:4282-4286, 1989.
244. Balkwill FR: Interferons. Lancet i:1060-1063, 1989.
245. Meyers JD, Flournoy N, Sanders JE, et al: Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 107:809-816, 1987.
246. Ascensao JL, Miller KB, Bilgrami S, et al: Long-term follow up of immunotherapy with interferon (IFN) after marrow transplantation (BMT) for patients (pts) with lymphomas-Hodgkin (HD) and non-Hodgkin (NHL) (abstract 466). Blood 88(Suppl 1): 119a, 1996.
247. Malkovsky M, Loveland B, North M, et al: Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature 325:262-265, 1987.
248. Welte K, Ciobanu N, Moore MA, Mertelsmann R, et al: Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood 64:380-385, 1984.
249. Velardi A, Varese P, Grossi CE, et al: Cytolytic function of clonable T cells after human bone marrow transplantation. Blood 75:1364-1369, 1990.
250. Symann M, Bosly A, Gisselbrecht C, et al: Immune reconstitution after bone-marrow transplantation. Cancer Treat Rev 16 (Suppl A):15-19, 1989.
251. Larsson EL, Joki AL, Stalhandske T: Mechanism of action of the new immunomodulator LS 2616 on T cell responses. Int J Immunopharmacol 9:425-31, 1987.
252. Bengtsson M, Simonsson B, Carlsson K, et al: Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation: A pilot study in patients with acute myeloid leukemia. Transplantation 53:882-888, 1982.
253. Kalland T: Regulation of natural killer progenitors: Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 144:442-476, 1990.
254. Kalland T, Alm G, Stalhandske T: Augmentations of mouse natural killer cell activity by LS2626, a new immunomodulator. J Immunol 134:3956-3961, 1985.
255. Kalland T: Effects of the immunomodulator LS2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 46:3018-3022, 1986.
256. Gaspari AA, Cheng SF, DiPersio JF, et al: Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 33:711-717, 1995.
257. Sender DM, Stemmer S, Johnson T, et al: High-dose 90Y-Mx-DTPA-BrE-3 and autologous hematopoietic stem cell support for the treatment of advanced breast cancer: A phase I trial. Cancer Res 55:5921S-5924S, 1995.
258. Chan CM, Baratta FS, Ozzello L, et al: Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 30:243-261, 1994.
259. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
260. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
261. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4:19-26, 1993.
262. HER2 antibody for human cancer treatment. Proc Natl Acad Sci USA 89:4285-4289, 1992.
263. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of recombinant human anti-HER2 monoclonal antibody in stage IV breast cancer: HER2 shedding dependent pharmacokinetics and antitumor activity (abstract 113). Proc Am Soc Clin Oncol 14:103, 1995.
264. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791, 1996.
265. Sasaki A, Boyce BF, Story B, et al: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995.
266. van der Pluijm G, Vloedgraven H, van Beek E, et al: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705, 1996.
267. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493, 1996.
268. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993.
269. Foulds L: The experimental study of tumor progression: A review. Cancer Res 14:327-339, 1954.
270. Jendraschak E, Sage EH: Regulation of angiogenesis by SPARC and angiostatin: Implications for tumor cell biology. Semin Cancer Biol 7:139-146, 1996.
271. Weidner N, Semple J, Welch WR, et al: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
272. O'Reilly MS, Holmgren L, Chen C, et al: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Medicine 2:689-692, 1996.
273. Folkman J: Clinical implications of angiogenesis research. N Engl J Med 333:1757-1763, 1995.
274. Ahmad A, Hart IR: Biology of tumor micro metastasis. J Hematother 5:525-535, 1996.
275. Millar A, Brown P, Cornish A, et al: Tumor marker levels during Marimastat therapy (letter). Lancet 348:263-264, 1996.
276. Curtis RE, Boice JD Jr, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751, 1992.
277. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group. J Clin Oncol 13:1557-1563, 1995.
278. Diamandidou E, Buzdar AU, Smith TL, et al: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center Experience. J Clin Oncol 14:2722-2730, 1996.
279. Traweek ST, Slovak ML, Nademanee AP, et al: Myelodysplasia occurring after autologous bone marrow transplantation (ABMT) for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) (abstract 1805). Blood 82(Suppl 1):455a, 1993.
280. Chao NJ, Nademanee AP, Long GD, et al: Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 9:1575-1579, 1991.
281. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994.
282. Stone RM, Neuberg D, Soiffer R, et al: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535-2542, 1994.
283. Deeg HJ: Delayed complications after bone marrow transplantation. In: Bone Marrow Transplantation, edited by SJ Forman, KG Blume, ED Thomas, Boston, Blackwell Scientific, 1994, pp 538-544.
284. Hjermstad MJ, Kaasa S: Quality of life in adult cancer patients treated with bone marrow transplantation - Review of the literature. Eur J Cancer 31A:163-173, 1995.
285. Stewart A, Hays R, Ware J: The MOS short-form general health survey: Reliability and validity in a patient population. Med Care 26:724-735, 1988.
286. McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1:373-378, 1978.
287. Cassileth B, Lusk E, Brown L, et al: Psychological status of cancer patients and next of kin: Normative data from the profile of mood states. J Psychosoc Oncol 3:99-105, 1985.
288. Greer S, Moorey S, Watson M: Patients adjustment to cancer: The mental adjustment to cancer (MAC) scale vs clinical rating. J Psychosomat Res 33:373-377, 1989.
289. Bergner M, Bobbitt RA, Carter WB, et al: The Sickness Impact Profile: Development and final revisions of a health status measure. Med Care 19:787-805, 1981.
290. Derogatis LR: The Psychological Adjustment to Illness Scale (PAIS). J Psychosom Res 30:77-91, 1986.
291. Schipper H, Clinch J, McMurray A, et al: Measuring the quality of life of cancer patients: The Functional Living Index - Cancer: development and validation. J Clin Oncol 2:472-483, 1984.
292. Ware JE, Snow KK, Kosinski M, et al: SF-36 Health Survey: Manual and Interpretation Guide, Boston, The Health Institute, New England Medical Center, 1993.
293. McHorney CA, Ware JE, Raczek AE: The MOS 36-item short Form Health Survey (SF-36): Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 3:247-263, 1993.
294. Portenoy RK, Thaler HT, Kornblith AB, et al: The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics, and distress. Eur J Cancer 30A:1326-1336, 1994.
295. McQuellon RP, Russell GB, Cella DF, et al: Quality of life measurement in bone marrow transplantation: Development of the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 19:357-368, 1997.
296. Winer E, Lindley C, Hardee M, et al: Quality of life (QL) assessment in patients with breast cancer surviving 12 months or more following high dose chemotherapy with autologous bone marrow transplant (HDC-ABMT) (abstract 1328). Proc Am Soc Clin Oncol 11:383, 1992.
297. Hann DM, Jacobsen PB, Martin SC, et al: Quality of life following bone marrow transplantation for breast cancer: A comparative study. Bone Marrow Transplant 19:257-264, 1997.
298. Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: Estimates using decision analysis while awaiting clinical trial results. J Am Med Assoc 267:2055-2061, 1992.
299. Patient Referral to the National Cancer Institute's Autologous Bone Marrow Transplantation Clinical Trials: The Physician's Perspective. A Report on Focus Groups and In-Depth Interviews Conducted at the American Society of Clinical Oncology National Meeting, May 1995. Bethesda, MD: Office of Cancer Communications, National Cancer Institute, 1995.
300. McQuellon RP, Muss HB, Huffman SL, et al: Patient preferences for treatment of metastastic breast cancer: A study of women with early-stage breast cancer. J Clin Oncol 13:858-868, 1995.
301. Mathews J: NCI survey explores the M.D.'s perspective on ABMT trials. J Natl Cancer Inst 87:1510-1511, 1995.
302. Hadorn DC: Setting health care priorities in Oregon: Cost-effectiveness meets the rule of rescue. J Am Med Assoc 265:2218-2225, 1991.
303. Peters WP, Rogers MC: Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 330:473-477, 1994.
304. Light DW: Life, death, and the insurance companies. N Engl J Med 330:498-500, 1994.
305. Richards MA, Braysher S, Gregory WM, et al: Advanced breast cancer: Use of resources and cost implications. Br J Cancer 67:856-860, 1993.
306. Gilbert CJ: Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations. Pharma-cotherapy 16:101S-108S, 1996.
307. Lawless GD: Cost-effectiveness of autologous bone marrow transplantation. Am J Health System Pharm 52(Suppl 4):S11-S14, 1995.
308. Dillman RO, Barth NM, Mahdavi K, et al: The integration of high-dose chemotherapy and biotherapy: Initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center. Cancer Biother 10:25-36, 1995.
309. Peters WP, Ross M, Vredenburgh JJ, et al: The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 21(4 Suppl 7):25-31, 1994.
310. Ross M, Dukelow K, Kasprzak S, et al: Outpatient bone marrow transplantation: Two year update (abstract 930). Proc Am Soc Clin Oncol 14:316, 1995.
311. Meisenberg BR, Miller WE, McMillan R, et al: Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 15:11-17, 1997.
312. Schulman KA, Click HA: Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision. Monogr Natl Cancer Inst 19:45-50, 1995.
313. Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 321:807-812, 1989.
314. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.
315. Martelli M, Vignetti M, Zinzani PL, et al: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol 14:534-542, 1996.
316. Verdonck LF, Van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995.
317. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 12:2543-2551, 1994.